Cutaneous lupus erythematosus (LE) is a diverse group of autoimmuneconnective tissue disorders localised to the skin that can be associated with systemic lupus erythematosus (SLE) to varying degrees.
Cutaneous lupus erythematosus (CLE) is classified as:
Skin lesions of cutaneous lupus erythematosus can be subdivided into:
Lupus-specific changes
Clinical signs diagnostic of, or unique to, LE
Histology is diagnostic for LE; vacuolarinterfacedermatitis
Lupus-nonspecific changes
Clinical signs found not only in LE, but also in other connective tissue diseases
Histology is not diagnostic for LE; reactive patterns seen.
Who gets cutaneous lupus erythematosus?
Cutaneous lupus erythematosus has an annual incidence of 4 cases per 100,000 people, and a prevalence of 73 cases per 100,000.
As with SLE, there is a marked female predominance with CLE particularly affecting women 20 to 50 years of age. However, all age groups and both sexes can be affected. Skin of colour is an important predisposing factor.
Up to 75% of patients with SLE develop cutaneous signs, and these may be the first indication of SLE in 25%.
What causes cutaneous lupus erythematosus?
The pathogenesis of cutaneous lupus erythematosus is multifactorial:
Geneticsusceptibility
High incidence among family members
Environmental factors
Cigarette smoking
Sun exposure
Medications
Innate and adaptive immune responses
autoantibodies.
What are the clinical features of cutaneous lupus erythematosus?
This is a brief overview of the clinical features of cutaneous lupus erythematosus. See the specific lupus pages for more detail – links are provided at the end under the ‘On DermNet’ heading.
Acute cutaneous lupus erythematosus
Acute cutaneous lupus erythematosus typically presents as transienterythematous patches associated with a flare of systemic lupus erythematosus.
Lupus-specific skin changes:
Localised acute CLE: malar ‘butterfly' rash – redness and swelling over both cheeks, sparing the nasolabial folds, lasting hours to days
Generalised acute CLE: diffuse or papularerythema of the face, upper limbs (sparing the knuckles), and trunk resembling a morbilliform drug eruption or viral exanthem
Toxic epidermal necrolysis-like acute CLE: is associated with lupus nephritis or cerebritis, and must be distinguished from drug-induced toxicepidermal necrolysis in a patient with SLE.
Malar 'butterfly' rash
Papular erythema of generalised ACLE
Sparing of knuckles
Subacute cutaneous lupus erythematosus
Subacute cutaneous lupus erythematosus is less commonly associated with SLE with approximately 50% having a mild form of SLE. It is thought 20–40% have drug-induced SCLE. It comprises 10–15% of cutaneous LE presentations. The skin changes are more persistent than those of ACLE.
Skin lesions of SCLE:
Occur on the trunk and upper limbs, triggered or aggravated by sun exposure
Present as a psoriasiformpapulosquamous rash or annular, polycyclicplaques with central clearing
Resolve to leave dyspigmentation and telangiectases, but no scarring.
Intermittent cutaneous lupus erythematosus
Intermittent CLE is better known as lupus tumidus, a dermal form of lupus erythematosus.
Skin lesions of lupus tumidus:
Occur on sun-exposed areas of skin, such as the face, neck, and upper anterior chest
Present as erythematous, round or annular, papules and plaques with a smooth surface
Resolve in winter without scarring.
Lupus tumidus, smooth red nodule on the cheek
Chronic cutaneous lupus erythematosus
Chronic cutaneous lupus erythematosus is the most common form of CLE, and about 25% of SLE patients have some form of CCLE.
Discoid lupus erythematosus
Discoid lupus erythematosus is the most common form of CCLE (80%) and is particularly prevalent and severe in patients with skin of colour. Only 1–2% of patients with localised DLE progress to SLE.
Skin lesions of DLE:
Are most commonly located on the scalp, ears, cheeks, nose, and lips
Present as destructive scaly plaques with follicular prominence (carpet tack sign) which can result in scarring alopecia
Heal slowly leaving post-inflammatory dyspigmentation and scarring.
Discoid LE
Discoid lupus erythematosus
Discoid lupus erythematosus
Lupus profundus
Lupus profundus is a mostly lobular panniculitis without vasculitis.
Skin lesions of lupus profundus:
Can develop at any site
Present as persistent, firm, deep, tender nodules
Resolve to leave dents in the skin due to atrophy of the fat.
Lupus profundus
Chilblain lupus erythematosus
Chilblain lupus erythematosus is an under-reported form of chronic CLE involving mainly the fingers and toes of smokers triggered by exposure to a moist cold environment. It may be familial with no association to SLE, or sporadic which can be associated with SLE.
Skin lesions of chilblain lupus:
Are often pruritic and painful
May ulcerate or develop hyperkeratoticfissuring
May heal leaving depigmentation and atrophic spindling of the distal phalange.
Chilblain lupus
Lupus tumidus
How do clinical features vary in differing types of skin?
Some forms of cutaneous lupus erythematosus, such as bullous lupus erythematosus and discoid lupus erythematosus, are particularly associated with skin of colour.
Dyspigmentation and scarring are complications of CLE that significantly impact quality of life for patients with skin of colour.
Malar 'butterfly' rash of SLE
Discoid LE
Discoid LE with dyspigmentation and scarring
Non-specific cutaneous lupus erythematosus
Non-scarring diffuse hair loss (unruly lupus hair)
Anifrolumab is a type 1 interferon receptor subunit blocker that has shown efficacy in systemic lupus as well as severe cutaneous lupus erythematosus
Belimumab is a B lymphocyte stimulator specific inhibitor and is licensed for both SLE and lupus nephritis, and may benefit recalcitrant cutaneous LE.
What is the outcome for cutaneous lupus erythematosus?
Cutaneous lupus erythematosus can be the presenting sign of SLE, as in acute CLE, or may evolve into SLE.
Female patients with CLE and Ro/La autoantibodies should be advised of the risk their baby may have neonatal lupus erythematosus including congenital heart block.
Chronic CLE tends to follow a chronic relapsing course for years, with flares in spring and summer, and resolution with scarring if untreated.
References
Arora JS, Kesler A, Min MS. A global retrospective study identifies higher rates of pernio in individuals with connective tissue disease. J Am Acad Dermatol. 2025;92(3):636-640. Pubmed
Chakka S, Krain RL, Concha JSS, Chong BF, Merola JF, Werth VP. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. Ann Transl Med. 2021;9(5):431. doi:10.21037/atm-20-5048. Journal
Filotico R, Mastrandrea V. Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol. 2018;153(2):216–29. doi:10.23736/S0392-0488.18.05929-1. Journal
Garelli CJ, Refat MA, Nanaware PP, Ramirez-Ortiz ZG, Rashighi M, Richmond JM. Current insights in cutaneous lupus erythematosus immunopathogenesis. Front Immunol. 2020;11:1353. doi:10.3389/fimmu.2020.01353. Journal
Goodfield M, Dutz J, McCourt C. Lupus erythematosus. In: Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D (eds). Rook’s Textbook of Dermatology, 9th edn, Wiley Blackwell, 2016: 51.1–39.
Hersh AO, Arkin LM, Prahalad S. Immunogenetics of cutaneous lupus erythematosus. Curr Opin Pediatr. 2016;28(4):470–5. doi:10.1097/MOP.0000000000000383. PubMed Central
Jafari AJ, McGee C, Klimas N, Hebert AA. Monoclonal Antibodies for the Management of Cutaneous Lupus Erythematosus: An Update on the Current Treatment Landscape. Clin Exp Dermatol. Published online September 7, 2024. Journal
Little AJ, Vesely MD. Cutaneous lupus erythematosus: current and future pathogenesis-directed therapies. Yale J Biol Med. 2020;93(1):81–95. PubMed Central
Petty AJ, Floyd L, Henderson C, Nicholas MW. Cutaneous lupus erythematosus: progress and challenges. Curr Allergy Asthma Rep. 2020;20(5):12. doi:10.1007/s11882-020-00906-8. PubMed Central
Stannard JN, Kahlenberg JM. Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus. Curr Opin Rheumatol. 2016;28(5):453–9. doi:10.1097/BOR.0000000000000308. PubMed Central